the Efficacy & Safety of Indobufen & Low-dose Aspirin in Different

Status Not yet recruiting

Clinical Trial Summary

A total of 210 coronary atherosclerosis patients without indications for stent implantation are included. The baseline values of platelet aggregation rate, plasmaThromboxaneB2 and urinary 11-dh ThromboxaneB2 are measured by Light Transmittance Aggregometry method and ELISA after aspirin 100 mg /d ≥5d. Then the patients are randomly divided into 7 groups: Group1: aspirin 100 mg/d; Group2: aspirin 100 mg /2d; Groups3: aspirin 100 mg / 3d; Groups4: morning 50mg evening 50mg; Group5: aspirin 75mg / d; Group6: aspirin 50mg / d; Group7: indobufen100mg bid. One month later,arachidonic acid-induced platelet aggregation rate , plasma TXB2 and urine 11-dh TXB2 are analyzed again. All patients are followed-up for 1 year. The stomach Intestinal reactions, small bleeding events are recorded.

Clinical Trial Description

A total of 210 coronary atherosclerosis patients without indications for stent implantation are included. Exclusion criteria：Aspirin resistance, uncontrolled hypertension (> 160 / 100mmHg),hemoglobin concentration <100g /L, hemorrhagic disease or a history of bleeding tendency, taking other nonsteroidal drugs, severe liver disease history, malignant tumor, active gastric mucosa bleeding, percutaneous coronary intervention history, coronary artery bypass surgery, cardiac function grade Ⅳ.The baseline values of platelet aggregation rate, plasma TXB2 and urinary 11-dh TXB2 are measured by LTA method and ELISA after aspirin 100 mg /d ≥5d. Then the patients are randomly divided into 7 groups: Group1: aspirin 100 mg/d; Group2: aspirin 100 mg /2d; Groups3: aspirin 100 mg / 3d; Groups4: morning 50mg evening 50mg; Group5: aspirin 75mg / d; Group6: aspirin 50mg / d; Group7: indobufen100mg bid. One month later,arachidonic acid-induced platelet aggregation rate , plasma TXB2 and urine 11-dh TXB2 are analyzed again. All patients are followed-up for 1month,6months and1 year. The stomach Intestinal reactions, small bleeding events ,whether to take proton pump inhibitors are recorded. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03230851
Study type	Interventional
Source	The First Affiliated Hospital with Nanjing Medical University
Contact	Li Chunjian, Ph.D
Phone	+86-25-83718836
Email	lijay@njmu.edu.cn
Status	Not yet recruiting
Phase	Phase 4
Start date	August 20, 2017
Completion date	August 10, 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02265146` - ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
Completed	`NCT02335086` - DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	N/A
Completed	`NCT00811772` - Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis	N/A
Recruiting	`NCT03322332` - Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries	N/A
Completed	`NCT02305953` - Cytokines and Vascular Inflammation in Psoriasis	N/A
Completed	`NCT01642173` - Assessment of Coronary Plaque Composition Using Optical Coherence Tomography	Phase 1
Completed	`NCT02316782` - Bifurcation Lesion Analysis and STenting / BLAST
Completed	`NCT00548613` - Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium	Phase 1
Terminated	`NCT00243308` - Serp-1 for the Treatment of Acute Coronary Syndrome	Phase 2
Recruiting	`NCT05105750` - A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis	Phase 4
Completed	`NCT01722214` - Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis	Phase 4
Terminated	`NCT01030328` - AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis	Phase 3
Suspended	`NCT00790764` - Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)	Phase 2
Active, not recruiting	`NCT01061398` - CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification	N/A
Completed	`NCT00431717` - Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes	N/A
Completed	`NCT00431977` - Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes	N/A
Recruiting	`NCT00155350` - Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients	Phase 4
Recruiting	`NCT05708547` - Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
Terminated	`NCT02440646` - Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
Terminated	`NCT01268319` - CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms